USPTO issues Notice of Allowance for Sunshine Biopharma's anti-tumor compound patent
 

Sunshine Biopharma Inc. is pleased to announce that it has recently received notification that the United States Patent and Trademark Office has issued a "Notice of Allowance" for the patent application covering its lead anti-tumor compound, Adva-27a. The allowed claims protect Adva-27a and extensively cover various formulations, derivatives and cancer applications.

More...